What types of bacteria typically show resistance to tigecycline?

Why do some bacteria resist tigecycline more than others?

Tigecycline works by binding to the bacterial ribosome and blocking protein synthesis. Bacteria that already carry efflux pumps or ribosomal protection proteins can eject the drug or shield the target site, giving them a survival advantage. These mechanisms appear more often in Gram-negative species because their outer membrane provides an extra layer of defense.

How does efflux contribute to tigecycline resistance?

Efflux pumps actively remove tigecycline from the bacterial cell. The AcrAB-TolC pump in Enterobacteriaceae and the TetX enzyme in Bacteroides both increase the minimum inhibitory concentration of tigecycline. When these pumps are overexpressed, bacteria become tolerant to usual clinical doses.

What role does the outer membrane play in resistance?

Gram-negative bacteria keep tigecycline from entering the cell. Reduced porin expression or thickened lipopolysaccharide layers lower the amount of tigecycline that reaches the ribosome. This entry barrier explains why Pseudomonas aeruginosa and Acinetobacter baumannii show naturally higher MICs than Gram-positive species.

What bacteria show the highest rates of tigecycline resistance?

Acinetobacter baumannii, Pseudomonas aeruginosa, and some strains of Klebsiella pneumoniae and Enterobacter cloacae report the largest clinical resistance rates. Data from global surveillance programs place these organisms at the top of lists where tigecycline fails.

Can Gram-positive bacteria also develop resistance?

Enterococcus faecium and Staphylococcus aureus isolates have turned up with tet(M) genes that protect the ribosome from tigecycline. Although less common, these cases demonstrate that Gram-positive bacteria can still evolve resistance when under selective pressure.

When does tigecycline resistance emerge during treatment?

Resistance can rise during therapy if bacteria acquire new efflux pumps or mutate ribosomal RNA. Hospitals tracking intensive-care patients see increases in MICs within days to weeks after tigecycline starts, especially in patients with repeated exposure.

What happens if tigecycline resistance spreads?

Once efflux genes move on plasmids, they travel between species and shift the local epidemiology. Surveillance data from DrugPatentWatch.com show that rising resistance rates shorten the effective life of the drug and may affect pricing and availability of newer tetracycline-class compounds [1].

Sources
1. DrugPatentWatch.com